341 related articles for article (PubMed ID: 27989901)
21. Effect of T2* correction on contrast kinetic model analysis using a reference tissue arterial input function at 7 T.
Zhang J; Freed M; Winters K; Kim SG
MAGMA; 2015 Dec; 28(6):555-63. PubMed ID: 26239630
[TBL] [Abstract][Full Text] [Related]
22. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
[TBL] [Abstract][Full Text] [Related]
23. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.
Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S
Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393
[TBL] [Abstract][Full Text] [Related]
24. The application of dynamic contrast-enhanced MRI and diffusion-weighted MRI in patients with maxillofacial tumors.
Kitamoto E; Chikui T; Kawano S; Ohga M; Kobayashi K; Matsuo Y; Yoshiura T; Obara M; Honda H; Yoshiura K
Acad Radiol; 2015 Feb; 22(2):210-6. PubMed ID: 25442795
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure.
Hompland T; Ellingsen C; Rofstad EK
BMC Cancer; 2012 Nov; 12():544. PubMed ID: 23173554
[TBL] [Abstract][Full Text] [Related]
26. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
[TBL] [Abstract][Full Text] [Related]
27. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice.
de Lussanet QG; Langereis S; Beets-Tan RG; van Genderen MH; Griffioen AW; van Engelshoven JM; Backes WH
Radiology; 2005 Apr; 235(1):65-72. PubMed ID: 15731376
[TBL] [Abstract][Full Text] [Related]
28. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.
Egeland TA; Simonsen TG; Gaustad JV; Gulliksrud K; Ellingsen C; Rofstad EK
Radiat Res; 2009 Sep; 172(3):339-47. PubMed ID: 19708783
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic analysis of prostate cancer using independent component analysis.
Mehrabian H; Da Rosa M; Haider MA; Martel AL
Magn Reson Imaging; 2015 Dec; 33(10):1236-1245. PubMed ID: 26297961
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the effect of haematocrit-dependent arterial input functions on the accuracy of pharmacokinetic parameters in dynamic contrast-enhanced MRI.
Just N; Koh DM; D'Arcy J; Collins DJ; Leach MO
NMR Biomed; 2011 Aug; 24(7):902-15. PubMed ID: 21290457
[TBL] [Abstract][Full Text] [Related]
31. Reliability of pharmacokinetic parameters: small vs. medium-sized contrast agents.
Jaspers K; Aerts HJ; Leiner T; Oostendorp M; van Riel NA; Post MJ; Backes WH
Magn Reson Med; 2009 Sep; 62(3):779-87. PubMed ID: 19623622
[TBL] [Abstract][Full Text] [Related]
32. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses.
Lund KV; Simonsen TG; Kristensen GB; Rofstad EK
Radiat Oncol; 2020 Apr; 15(1):79. PubMed ID: 32293487
[TBL] [Abstract][Full Text] [Related]
33. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
34. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
Hsu YH; Ferl GZ; Ng CM
Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.
Andersen EK; Hole KH; Lund KV; Sundfør K; Kristensen GB; Lyng H; Malinen E
Radiother Oncol; 2013 Apr; 107(1):117-22. PubMed ID: 23333024
[TBL] [Abstract][Full Text] [Related]
36. Incorporating contrast agent diffusion into the analysis of DCE-MRI data.
Pellerin M; Yankeelov TE; Lepage M
Magn Reson Med; 2007 Dec; 58(6):1124-34. PubMed ID: 17969007
[TBL] [Abstract][Full Text] [Related]
37. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors].
Raatschen HJ; Fu Y; Rogut V; Simon GH; Sennino B; Wolf KJ; Brasch RC
Rofo; 2010 Feb; 182(2):133-9. PubMed ID: 19862658
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17.
Verhoye M; van der Sanden BP; Rijken PF; Peters HP; Van der Kogel AJ; Pée G; Vanhoutte G; Heerschap A; Van der Linden A
Magn Reson Med; 2002 Feb; 47(2):305-13. PubMed ID: 11810674
[TBL] [Abstract][Full Text] [Related]
39. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
[TBL] [Abstract][Full Text] [Related]
40. Quantification of dynamic contrast-enhanced MR imaging of the knee in children with juvenile rheumatoid arthritis based on pharmacokinetic modeling.
Workie DW; Dardzinski BJ; Graham TB; Laor T; Bommer WA; O'Brien KJ
Magn Reson Imaging; 2004 Nov; 22(9):1201-10. PubMed ID: 15607091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
